目的 探讨2023—2025年辽宁省肿瘤医院口服靶向抗肿瘤药物使用情况，为该类药物的安全合理经济用药及规范化管理提供参考依据。方法 收集2023年1月1日—2025年12月31日辽宁省肿瘤医院口服靶向抗肿瘤药物的使用数据，逐年分析销售金额、用药频度（DDDs）、限定日费用（DDC）以及排序比（B/A）。结果 2023—2025年辽宁省肿瘤医院口服靶向抗肿瘤药物年销售金额呈逐年上升的趋势。伏美替尼的销售金额和DDDs逐年上升，在2025年销售金额和DDDs均位居第1，奥希替尼的销售金额和DDDs在近3年稳居在前2位。2023年上市的新药瑞波西利的销售金额和DDDs逐年上升。从DDDs排序可以看出，治疗非小细胞肺癌和乳腺癌的口服靶向药使用频率和临床选择性均较高。近3年辽宁省肿瘤医院口服靶向药的DDC值逐年下降，奥希替尼2023—2025年的B/A均为1，伏美替尼在2024—2025年的B/A也均为1，同步性良好。结论 辽宁省肿瘤医院在2023—2025年口服靶向抗肿瘤药物的使用较为合理，基本符合临床治疗的实际需求和国家政策要求。

Objective To analyze and discuss the use of oral targeted anti-tumor drugs in Liaoning Cancer Hospital from 2023 to 2025, and provide a reference for the rational application and standardized management. Methods To collect the usage data of oral targeted anti-tumor drugs in Liaoning Cancer Hospital from January 1, 2023 to December 31, 2025, and analyze the sales amount, DDDs, DDC, and B/A year by year. Results From 2023 to 2025, the annual sales amount of oral targeted anti-tumor drugs at Liaoning Cancer Hospital showed a trend of increasing year by year. The sales amount and DDDs of furmonertinib increased year by year. In 2025, the sales amount and DDDs of furmonertinib ranked first. The sales amount and DDDs of osimertinib remained in the top 2 in the past 3 years. The sales amount and DDDs of the newly launched drug ribociclib increased year by year in 2023. From the ranking of DDDs, it can be seen that the usage frequency and clinical selectivity of oral targeted drugs for treating non-small cell lung cancer and breast cancer are both relatively high. The DDC values of oral targeted drugs at Liaoning Cancer Hospital have decreased year by year in the past 3 years. The B/A ratio of osimertinib from 2023 to 2025 was 1, and the B/A ratio of furmonertinib from 2024 to 2025 was also 1, showing good consistency. Conclusion The use of oral targeted anti-tumor drugs in Liaoning Cancer Hospital is relatively reasonable during the period of from 2023 to 2025, which basically meets the actual clinical treatment needs of our hospital and the requirements of national policies.

R979.1